TICKERNERD
Menu
VRDNVRDNHealthcare · Biotechnology

VRDN Stock Forecast: Viridian Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 18 Sept 2026
$22
+0.32% on the day

The 17 Wall Street analysts covering Viridian Therapeutics, Inc. hold a median 12-month price target of $36 — +61.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 47 of 100 as at 18 Sept 2026 — in the lower half.

Market cap
$2.5B
Ticker Nerd rank
47 / 100
Median analyst target
$36
Analysts covering
17
Revenue$284K+278.7% y/y
Operating income−$126.3M
Net income−$127.1M
Free cash flow−$106.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+3.6%
1M
−8.1%
YTD
−29.3%
1Y
+12.1%
From 52W high
−34.9%
From 52W low
+65.4%
$13
$34
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

VRDN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Viridian Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 18 Sept 2026
47 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
91
Volatility
80
Momentum
59
Quality
57
Value
53
Accruals
50
Revisions
45
Size
33
Issuance
7

Growth (91): Sales and profits are climbing, and climbing faster than before.

Issuance (7): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

VRDN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on VRDN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50Oct 25Jan 26Apr 26Jul 26VRDNHigh $50Median $36Low $22

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says17 analysts
17 Buy0 Hold0 Sell
Low $22Median $36High $50

The green dot is the last close — the median target sits +61.4% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 7 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
7 Aug 2026RBC CapitalMaintainsOutperform$35 → $36
7 Aug 2026Truist SecuritiesMaintainsBuy$38 → $39
30 June 2026NeedhamMaintainsBuy—
30 June 2026NeedhamMaintainsBuy$32 → $34
30 June 2026RBC CapitalMaintainsOutperform$34 → $35
30 June 2026RBC CapitalMaintainsOutperform—
30 June 2026Truist SecuritiesMaintainsBuy$35 → $38
30 June 2026Truist SecuritiesMaintainsBuy—
30 June 2026WedbushMaintainsOutperform—
30 June 2026WedbushMaintainsOutperform$32 → $43
29 June 2026NeedhamReiteratesBuy$32
29 June 2026NeedhamReiteratesBuy—
29 June 2026Wells FargoUpgradeOverweight—
29 June 2026Wells FargoUpgradeOverweight$20 → $31
15 May 2026Evercore ISI GroupMaintainsOutperform—
6 May 2026RBC CapitalMaintainsOutperform—
5 May 2026NeedhamReiteratesBuy—
21 Apr 2026Truist SecuritiesMaintainsBuy—
8 Apr 2026WedbushMaintainsOutperform—
7 Apr 2026Goldman SachsMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. VRDN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

VRDN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Sept 2026, Viridian Therapeutics, Inc. returned +12.1% against +16.3% for the S&P 500, dividends included.

VRDN vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140160180Oct 25Jan 26Apr 26Jul 26VRDNS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

VRDN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
7
Fundamentals

Viridian Therapeutics, Inc. (VRDN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−6.6×

Cheaper than 91% of US stocks

Price / sales
35.0×

Cheaper than 7% of US stocks

Price / book
4.5×

Cheaper than 23% of US stocks

EV / EBITDA
−4.6×

Cheaper than 78% of US stocks

Growth & margins
Revenue growth (YoY)
278.7%

Higher than 97% of US stocks

Earnings growth (YoY)
278.7%

Higher than 92% of US stocks

Gross margin
—
Operating margin
−44460.6%

Higher than 1% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−65.7%

Higher than 18% of US stocks

Return on assets
−30.2%

Higher than 14% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Viridian Therapeutics, Inc. (VRDN) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Viridian Therapeutics, Inc. has a market value of $2.5B and an enterprise value of $1.8B.

  • Revenue in the twelve months to 30 June 2026: $71.1M. The latest quarter grew 278.7% year on year.

  • Net income over the same four quarters: −$387.0M, a −544.1% net margin.

  • Diluted earnings per share, trailing twelve months: $−3.37.

  • Free cash flow in the twelve months to 30 June 2026: −$335.0M.

  • Shares outstanding: 113.2M.

  • Trailing P/E: −6.6×; forward P/E: −7.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Viridian Therapeutics, Inc. employs 252 people — $282K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 18 Sept 2026

Data provided by Twelve Data

Peers

VRDN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
VRDNViridian Therapeutics, Inc.$2.5B
47
HRMYHarmony Biosciences Holdings, Inc.$2.4B
85
MLYSMineralys Therapeutics, Inc.$2.5B
25
VERAVera Therapeutics, Inc.$2.4B
28
PHVSPharvaris NV$2.5B
42
BEAMBeam Therapeutics, Inc.$2.5B
50
SLSSELLAS Life Sciences Group, Inc.$2.3B
64

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Viridian Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest VRDN news & analysis

Viridian Therapeutics: Two Products, One Commercial Buildout

Seeking Alpha · 17 Sept 2026neutral

Viridian Therapeutics is shifting its focus from regulatory risk to launch execution following FDA approval of Lumvoa for thyroid eye disease. The company aims to leverage a shared commercial infrastructure for both Lumvoa and investigational elegrobart, potentially improving franchise economics and operational efficiency, though its valuation remains demanding with no near-term asset-based floor.

Why it matters — VRDN watchers would care because the company's future profitability now hinges on successful commercialization of Lumvoa and on realizing efficiencies from sharing infrastructure with the pipeline candidate elegrobart.

Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference

Business Wire · 2 Sept 2026neutral

Viridian Therapeutics announced that its senior management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on September 8, 2026, at 12:45pm ET. A live webcast of the chat will be available under "Events and Presentations" on the company's investor relations site.

Why it matters — A VRDN watcher would care because the fireside chat offers an opportunity for investors and analysts to hear directly from Viridian's senior management at a prominent healthcare conference.

Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results

Business Wire · 6 Aug 2026positive

Viridian Therapeutics, a biotechnology company focused on autoimmune and rare diseases, reported recent business highlights and financial results for the second quarter ended June 30, 2026. The company noted encouraging early indications from the recent launch of Lumvoa as it transitions into a commercial-stage company.

Why it matters — VRDN watchers would care because this marks an early update on the commercial launch of the company's medicine, Lumvoa, reflecting its transition into a commercial-stage business.

FAQ

Frequently asked questions about VRDN stock

What is the VRDN stock price forecast for 2026-2027?

The 17 Wall Street analysts covering Viridian Therapeutics, Inc. have a median 12-month price target of $36, with estimates ranging from $22 to $50. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is VRDN stock a buy right now?

Of the 17 analysts covering Viridian Therapeutics, Inc., 17 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Viridian Therapeutics, Inc. 47 out of 100 across roughly 4,600 US stocks as at 18 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank VRDN?

As at 18 Sept 2026, Viridian Therapeutics, Inc. ranks 47 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (91 of 100).

Will VRDN stock go up?

No one can know that. What the data says: the median 12-month target from 17 analysts implies +61.4% from the last close, and Ticker Nerd's factor model ranks Viridian Therapeutics, Inc. 47 out of 100 as at 18 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the VRDN stock forecast for 2030?

No analyst covering Viridian Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VRDN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $22 to $50 over the next 12 months.

How has VRDN stock performed over the past year?

Viridian Therapeutics, Inc. returned +12.1% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Viridian Therapeutics, Inc. do?

Viridian Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for autoimmune and rare diseases, with a primary emphasis on thyroid eye disease.

What is the latest news on VRDN?

The most recent item we track (Seeking Alpha, 17 Sept 2026): "Viridian Therapeutics: Two Products, One Commercial Buildout". Viridian Therapeutics is shifting its focus from regulatory risk to launch execution following FDA approval of Lumvoa for thyroid eye disease. The company aims to leverage a shared commercial infrastructure for both Lumvoa and investigational elegrobart, potentially improving franchise economics and operational efficiency, though its valuation remains demanding with no near-term asset-based floor.

Company

About Viridian Therapeutics, Inc.

Viridian Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for autoimmune and rare diseases, with a primary emphasis on thyroid eye disease. The company’s current pipeline centers on antibody-based programs designed to target validated disease pathways, including intravenous and subcutaneous candidates for thyroid eye disease and additional assets aimed at autoimmune conditions. Viridian Therapeutics also advances FcRn inhibitor programs, expanding its work across immunology-focused indications. The company operates in the biotechnology and specialty therapeutics market, where it contributes to the development of differentiated medicines for patients with serious conditions that have limited treatment options. Headquartered in Waltham, Massachusetts, Viridian Therapeutics combines antibody discovery and protein engineering to support its research, clinical development, and future commercialization efforts.

CEO Mr. Stephen F. Mahoney J.D., MBA · 252 employees · United States · https://www.viridiantherapeutics.com